Your doctor will check your blood at regular intervals during treatment. When you start taking these medications, your doctor may do blood tests once every two weeks. After the first couple of visits, ...
Patients with advanced estrogen receptor (ER)-positive breast cancer that progressed on CDK4/6 inhibitors had better survival if they continued CDK4/6 inhibition plus endocrine therapy rather than ...
SAN ANTONIO — For patients with advanced hormone receptor-positive, HER2-negative breast cancer, health-related quality of life is the same whether they receive CDK4/6 inhibitors in the first or ...
No significant OS advantage was found among CDK4/6 inhibitors for HR-positive, HER2-negative metastatic breast cancer. Real-world data showed median OS of 54.6 months for Ibrance, 59 months for ...
A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published in Nature ...
SAN ANTONIO — A machine learning model, which incorporates both clinical and genomic factors, helps predict which patients with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2 ...
A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data in predicting which patients with hormone receptor (HR ...
Electronic patient reported outcomes in breast cancer patients receiving adjuvant chemotherapy with doxorubicin/cyclophosphamide combined with paclitaxel compared to ...
HOUSTON -- Progression-free survival for 6 months (PFS6) in recurrent/progressive high-grade meningioma improved more than threefold versus historical outcomes in patients who received the CDK4/6 ...
Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, necessitating new therapeutic strategies. CDK4/6 inhibitors show promise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results